-
-
Those who suffer from stroke and ultimately those with head trauma, brain injury or in cardiac arrest may in the not-too-distant future have another weapon in the physician arsenal to fight brain swelling, the result of disease or injury that often causes more damage than the original trauma.
-
OmniSonics Medical Technologies (Wilmington, Massachusetts), a developer of medical devices to treat vascular occlusive disease, last month reported the final close of its Series C round of financing, producing an aggregate total of $43 million for the round.
-
A Canadian company has created a device that it says can detect a heart attack up to eight minutes before a patient experiences symptoms of the attack, then can alert emergency medical staff and direct them to the patients exact location. The Vital Positioning System (VPS), developed by Medical Intelligence (Quebec City, Quebec), combines a digital wireless ECG, artificial intelligence and telecommunications technology in a single belt worn around the patients thorax.
-
The largest cardiovascular companies had plenty of news to crow about in the latter part of February and early March as they jockeyed for position in various key sectors of the cardiovascular device market. Boston Scientific (Natick, Massachusetts) made the biggest news, reporting on March 4 that it had received its much-anticipated FDA approval to market the Taxus Express2 paclitaxel-eluting coronary stent system.
-
-
-
Cognitive Effects of Estrogen Therapy; Vitamin Therapy and Restenosis; Echinacea and the Common Cold; Effects of Paxil in Children Under 18; FDA Actions.
-
-
The womens health initiative reported their results on cognition and dementia combining the canceled estrogen-only arm with the canceled estrogen-progestin arm of the randomized trial; the data are derived from an ancillary study of the trial entitled The Womens Health Initiative Memory Study (WHIMS).
